The MAVORIC phase III trial, comparing MOG and vorinostat in previously treated CTCL, reported that skin rash was present in 24% of patients, with photosensitivity, eczematous dermatitis, erythroderma, and neutrophilic eccrine hidradenitis algo being reported. This evidence concerns the gene MOG and Skin rash.